THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 20, 2018

Primary Completion Date

August 29, 2022

Study Completion Date

September 29, 2027

Conditions
Aortic Regurgitation
Interventions
DEVICE

JenaValve Pericardial TAVR System

TAVR with JenaValve Pericardial Valve and Delivery System

Trial Locations (19)

2333

Leiden University Medical Center, Leiden

3062

Erasmus University Medical Center, Rotterdam

3435

St. Antonius Hospital, Nieuwegein

10032

New York-Presbyterian/ Columbia University Medical Center, New York

13353

Deutsches Herzzentrum Berlin, Berlin

20010

MedStar Washington Hospital Center, Washington D.C.

20246

Universitäres Herzzentrum Hamburg, Hamburg

30309

Piedmont Healthcare, Atlanta

30322

Emory University Hospital, Atlanta

32545

Herz- und Diabeteszentrum NRW Ruhr-Universität Bochum Bad Oeynhausen, Bad Oeynhausen

48109

University of Michigan, Ann Arbor

50937

Herzzentrum der Universität zu Köln, Cologne

53127

Universitätsklinikum Bonn, Bonn

60323

Universitätsklinikum Frankfurt, Frankfurt

61231

Kerckhoff-Klinik GmbH Bad Nauheim, Bad Nauheim

75201

Baylor Scott & White Research Institute, Dallas

90048

Cedars Sinai Medical Center, Los Angeles

94109

California Pacific Medical Center Research Institute, San Francisco

98195

University of Washington, Seattle

Sponsors
All Listed Sponsors
lead

JenaValve Technology, Inc.

INDUSTRY

NCT02732704 - THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study | Biotech Hunter | Biotech Hunter